Ifabotuzumab (anti-EphA3) is an IgG1κ antibody targeting EphA3 (KD=610 pM). Ifabotuzumab (anti-EphA3) induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab (anti-EphA3) reduces human idiopathic pulmonary fibrosis (IPF) CCR10+ cells and improves pulmonary fibrosis.
Specification: Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC-HPLC), Lot by Lot
Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/AB191893-SCI_734a233f70800216c998823164fe151a.pdf
- UPC:
- 51201539
- Condition:
- New
- Availability:
- 4-8 weeks
- Weight:
- 0.07 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- Ab191893-100μg
- CAS:
- 2147698-66-4
- Product Size:
- 100μg